Quartz·1 min read·medium
Kailera's oral weight loss pill met its trial goal, but nausea hit 70% of patients
✦AI Summary
Kailera's stock fell 10% following Phase 3 clinical trial results for its weight loss pill, HRS-7535. While the drug met its primary efficacy goals, 70% of participants reported experiencing nausea.
Kailera stock dropped 10% after Phase 3 data showed roughly 70% of patients on HRS-7535 experienced nausea
healthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in